Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
Open Access
- 8 February 2005
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 92 (4) , 628-630
- https://doi.org/10.1038/sj.bjc.6602394
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Hepatocellular carcinomaPublished by Elsevier ,2003
- A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinomaCancer Chemotherapy and Pharmacology, 2003
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinomaAnnals of Oncology, 2000
- The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicinAnnals of Oncology, 1998
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trialCancer, 1988
- LIPOSOMES AS DRUG CARRIERS IN CANCER-THERAPY1984